Evodiamine is one of the major bioactive compounds that have been isolated and purified from the fruit of Evodiae fructus.
Introduction
Most anticancer agents eradicate tumor cells by the induction of apoptosis. Recent studies have suggested that the various anticancer agents used against cancer mediate their effects by induction of apoptosis of the cancer cells (1 -3) . It is suggested that there are several apoptotic pathways in cells responsive to apoptotic stimuli, such as the death receptor -mediated pathway, the mitochondrial apoptotic pathway, and the endoplasmic reticulum pathway (4 -6) . Although each pathway is initially mediated by different mechanisms, they share a common final phase of apoptosis, consisting of the activation of the executioner caspases and dismantling of substrates critical for cell survival (7) .
Induction of apoptosis by chemotherapeutic agents, such as DNA-damaging agents, topoisomerase inhibitors, and antimitotic agents, is largely mediated by the mitochondrial apoptotic pathways (2) , which in turn increase the permeability of outer mitochondrial membrane (8 -10) . This involves release of mitochondrial apoptotic components, such as cytochrome c, apoptosis-inducing factor (AIF), second mitochondrial-derived activator of caspase, endonuclease G, and Omi1/HtrA2 (11 -14) . The released apoptotic proteins initiate caspase activation and trigger caspase-mediated apoptotic DNA fragmentation and eventually cell death. On the other hand, mammalian cells in a certain circumstance can undergo caspase-independent apoptosis that is mediated by the disruption of the mitochondrial membrane potential and the translocation of AIF and endonuclease G to nucleus where they induce chromatin condensation and/or large-scale DNA fragmentation (15) .
Leukemia is grouped into two. The one is lymphocytic leukemia originated from lymphocytes in the bone marrow and the other is myelogenous leukemia mainly originated from granulocytes or monocytes (16) . Both acute myelogenous leukemia and adult-onset acute lymphocytic leukemia are aggressive diseases that respond poorly to conventional chemotherapy. The primary cause of treatment failures in patients with these diseases is the emergence of multidrug resistance, including decreased drug uptake, increased drug export, modification of targets to drug action, decreased apoptosis, and increased drug metabolism (17) . Leukemia cells, in turn, have adopted various mechanisms to resist apoptosis. Natural inhibitors of apoptosis, such as Bcl-2 and inhibitor of apoptosis protein (IAP) family members, protect the tumor cells from the apoptotic effects of various antineoplastic agents. These proteins may impair the ability to achieve remission and cure with chemotherapy. In trying to overcome drug resistance and improve clinical outcomes, attention is turning to developing therapeutic agents that overcome defects in the apoptotic pathways. Current chemotherapy protocols for leukemia commonly use drugs that interfere with DNA replication and induce apoptosis primarily in replicating cells (18, 19) . However, these regimens may not effectively discriminate between normal and malignant cells, thus causing substantial damage to normal tissues. For this reason, it is important to develop treatments that can more specifically target the leukemic cell population without showing the cytotoxicity to normal cells.
A variety of plant antioxidants, such as dietary and herbal polyphenols and carotenoids, with anticancer activity have been identified in both epidemiologic studies and experimental model systems (20 -23) . Natural products have provided a large number of currently used chemotherapeutics and will continue to be an important component of drug discovery (24, 25) . Evodiamine, an alkaloidal component extracted from the fruit of Evodiae fructus, has been reported to inhibit various tumor cell proliferations, including monocytic leukemia (26) , melanoma (27) , prostate cancer (28) , and breast cancer cell (29) . However, the mechanism underlying its antiproliferative, antimetastatic, and apoptotic activities is poorly defined yet.
In the present study, we examined the apoptosisinducing potential of evodiamine in U937 cell lines and dissected the evodiamine-induced apoptotic signaling pathway. Our results showed that evodiamine induced relatively high levels of apoptosis in the majority of U937 cells through both caspase-dependent and caspase-independent pathways. Furthermore, evodiamine induced cell death in both Bcl-2-overexpressed and active Akt-overexpressed U937 cells without effect on the viability of human normal peripheral blood mononuclear cells (PBMC).
Materials and Methods

Cell Lines
The human leukemic U937 cells were obtained from the American Type Culture Collection (Rockville, MD). The cells were cultured in RPMI 1640 supplemented with 2 mmol/L L-glutamine, 100 units/mL penicillin, 100 Ag/mL streptomycin, and 10% fetal bovine serum. Evodiamine was directly added to cell cultures at the indicated concentrations, whereas untreated cells contained the solvent alone. Anti -poly(ADP-ribose) polymerase (PARP), anti -phospholipase C-g1 (PLC-g1), anti-procaspase-3, antiBcl-2, anti-AIF, and anti -cytochrome c antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibody against X-linked IAPs (XIAP) was obtained from R&D Systems (Minneapolis, MN), and benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (z-VAD-fmk) was obtained from Biomol (Plymouth Meeting, PA). Evodiamine was purchased from Calbiochem (San Diego, CA).
Annexin V and 7-Aminoactinomycin D Staining Enumeration of apoptotic cells was done using FITCconjugated Annexin V (BD Pharmingen, San Jose, CA) and 7-aminoactinomycin D (7-AAD). Cells were washed twice in cold PBS and resuspended in Annexin V -binding buffer (BD Pharmingen) at a concentration of 3 Â 10 6 per mL. This suspension (100 AL) was stained with 5 AL of Annexin V-FITC and 5 AL 7-AAD. 7 
DNA Fragmentation Assay
After treatment with drugs, U937 cells were lysed in buffer containing 10 mmol/L Tris (pH 7.4), 150 mmol/L NaCl, 5 mmol/L EDTA, and 0.5% Triton X-100 for 30 minutes on ice. Lysates were vortexed and cleared by centrifugation at 10,000 Â g for 20 minutes. Fragmented DNA in the supernatant was extracted with an equal volume of neutral phenol-chloroform-isoamyl alcohol mixture (25:24:1) and analyzed electrophoretically on 2% agarose gels containing 0.1 Ag/mL ethidium bromide.
Asp-Glu-Val-Asp-ase Activity Assay for Evaluation of Caspase Activation
To evaluate Asp-Glu-Val-Asp-ase (DEVDase) activity, cell lysates were prepared after their respective treatment with evodiamine. Assays were done in 96-well microtiter plates by incubating 20 Ag of cell lysates in 100 AL reaction buffer [1% NP40, 20 mmol/L Tris-HCl (pH 7.5), 137 mmol/L NaCl, 10% glycerol] containing the caspases substrate (DEVD-chromophore p-nitroanilide) at 5 Amol/L. Lysates were incubated at 37jC for 2 hours. Thereafter, the absorbance at 405 nm was measured with a spectrophotometer. 4 ¶,6-Diamidino-2-Phenylindole Staining for Nuclei Condensation and Fragmentation U937 cells were treated with 0.6 Amol/L evodiamine or evodiamine plus 50 Amol/L z-VAD for 18 hours. The cells were fixed with 1% paraformaldehyde on slide glass for 30 minutes at room temperature. After washing with PBS, 300 nmol/L 4 ¶,6-diamidino-2-phenylindole (Roche, Indianapolis, IN) was added to the fixed cells for 5 minutes, after which they were examined by fluorescence microscopy. Apoptotic cells were identified by condensation and fragmentation of nuclei. The 4 ¶,6-diamidino-2-phenylindole staining experiments were done in duplicate.
Confocal Immunofluorescence Microscopy for AIF Translocation Cells (5 Â 10 4 ) were cytospun onto noncharged slides (Becton Dickinson), fixed for 20 minutes in 4% paraformaldehyde, washed again with PBS, and permeabilized with 1% Triton X-100 for 30 minutes at room temperature and washed with TBS containing 0.1% sodium azide. To reduce nonspecific antibody binding, slides were incubated in 1% bovine serum albumin in TBS for 1 hour at room temperature before incubation with rabbit polyclonal antibody to human AIF (Santa Cruz Biotechnology) overnight at 4jC. Slides were then washed for 30 minutes in TBS containing 0.1% sodium azide and incubated for 1 hour with FITC-conjugated secondary antibody (Vector, Burlingame, CA). Nuclei were stained with propidium iodide (Sigma) for 15 minutes at room temperature. Slides were washed and air dried before they were mounted on coverslips with ProLong Antifade mounting medium (Molecular Probes, Eugene, OR), and then they were examined under a Zeiss LSM 510 multiphoton confocal microscope (Zeiss, Gőettingen, Germany).
Separation of Human PBMCs
Blood was obtained from three healthy adult volunteers (10 mL plus 0.1 mL of heparin, 1,000 units/mL). The blood was centrifuged at 2,000 rpm with a vasculant rotor for 10 minutes at room temperature. The layer of white cells plus some RBCs was taken and transferred to tubes with 0.1 mol/L sodium phosphate buffer (PBS; pH 7.4) and centrifuged at 1,000 rpm for 10 minutes. The white layer was taken, completed to 10 mL PBS, and placed on 5 mL Ficoll-Hypaque, and after centrifugation at 2,000 rpm for 30 minutes, the monocyte layer was taken and placed and cultured in RPMI 1640 containing 10% fetal bovine serum.
Cell Counting Kit-8 Assay Cell counting kit-8 assay is nearly proportional to the cell number and thus can be used to determine cell proliferation and cytotoxicity. PBMCs (2 Â 10 3 ) per well were added to the 96-well culture plates. The cells were exposed to various concentrations of evodiamine. The cells then were grown for an additional 18 hours, and the cell counting kit-8 assay was carried out using the manufacturer's instructions (Dojindo, Kumamoto, Japan).
Me a surement of Re ac tive Ox ygen Sp e cie s Generation
The generation of reactive oxygen species (ROS) was measured by a flow cytometry analysis using 2 ¶,7 ¶-dichlorodihydrofluorescein diacetate as a substrate. Briefly, U937 cells were incubated with 0.6 Amol/L evodiamine in the presence or absence of 10 mmol/L N-acetyl-L-cysteine (NAC) for 18 hours and loaded with 10 Amol/L 2 ¶,7 ¶-dichlorodihydrofluorescein diacetate 1 hour before harvesting. The fluorescence was measured at the desired time intervals by flow cytometry. The ROS generation was assessed by the dichlorofluorescein fluorescence intensity (FL-1, 530 nm) from 10,000 cells with a FACSCalibur flow cytometer (Becton Dickinson). Control cells were subjected to the same manipulation, except for treatment with the evodiamine.
Results Evodiamine Induces Apoptosis in U937 Cells
Human leukemic U937 cells were treated with evodiamine (0.2 -0.8 Amol/L). We first determined apoptosis in U937 cells using flow cytometric analysis to detect hypodiploid cell populations. As shown in Fig. 1A , treatment of U937cells with evodiamine resulted in a markedly increased accumulation of sub-G 1 phase cells in a dosedependent manner. We next analyzed whether treatment with evodiamine caused the activation of caspases, a key executioner of apoptosis. Exposure of U937 cells to evodiamine strongly stimulated DEVDase activity and led to a reduction of the protein levels of XIAP and 32-kDa caspase-3 precursor together with a concomitant cleavage of PLC-g1 and PARP, a substrate protein of caspases (Fig. 1B) . Next, we carried out time kinetics studies of the apoptotic effects of evodiamine on U937 cells. Because the dose required for half-maximal inhibition of viability was f0.6 Amol/L, this single concentration was used for further assessment of apoptosis. Evodiamine treatment induced markedly increase of sub-G 1 population after 18 hours of treatment (Fig. 1C) . The levels of procaspase-3 were progressively degraded from 12 to 24 hours after evodiamine treatment in U937 cells. We further assessed the DEVDase activity and proteolytic cleavage of PLC-g1. In parallel with the degradation of caspase-3, the activity of DEVDase and the 60-kDa cleavage product of PLC-g1 were progressively increased from 18 to 24 hours in U937 cells following treatment with 0.6 Amol/L evodiamine ( Fig. 1C and D) .
Evodiamine-Induced Apoptosis Was Partly Mediated by Caspase-Dependent Pathway
We examined the involvement of caspase in evodiamineinduced apoptosis. Not only evodiamine induced the degradation of procaspase-3 and produced 60-kDa cleavage product of PLC-g1, a well-known substrate of caspase ( Fig. 2A) , but it increased DEVDase activity (Fig. 2B ). Cells treated with evodiamine showed DNA fragmentation, which is a hallmark of apoptosis (Fig. 2C) . We also found that pretreatment with z-VAD-fmk, a pancaspase inhibitor, prevented DNA fragmentation in cells treated with evodiamine (Fig. 2C) . A general and potent inhibitor of caspases z-VAD-fmk prevented all these caspase-related events ( Fig. 2A -C) . However, z-VAD-fmk did not completely block the nuclear condensation and formation of apoptotic bodies caused by evodiamine treatment (Fig. 2D) . In addition, z-VAD-fmk treatment partly prevented evodiamine-induced cell death as determined by FACS analysis (Fig. 2E) . These results suggest that evodiamine-induced cell death was partly mediated by caspase-dependent pathway and caspase-independent cell death in the presence of z-VAD-fmk.
Caspase-Independent Cell Death Was Not Caused by Necrotic Cell Death
To reveal whether caspase-independent cell death induced by evodiamine treatment in U937 cells is apoptosis or necrosis, we examined the translocation of membrane phosphatidylserine from the inner to outer leaflet of the plasma membrane. Because translocation of phosphatidylserine to external cell surface occurs during early apoptosis and necrosis, Annexin V-FITC and vital dye, such as 7-AAD, were used to distinguish apoptotic cells from necrotic cells (30) . As shown in Fig. 3 , the incidence of early apoptotic 7-AAD À /Annexin V + cells was increased in evodiamine-treated cells but the incidence of necrotic 7-AAD + /Annexin V À or 7-AAD + /Annexin V + cells was not. In addition, pretreatment with 50 Amol/L z-VAD-fmk decreased the population of early apoptotic 7-AAD À / Annexin V + cells increased by evodiamine treatment. These results suggest that evodiamine-induced cell death was not mediated by necrotic cell death but apoptosis.
Evodiamine-Induced Apoptosis Seems to be Independent on the Formation of ROS Numerous investigations have documented that oxidative stress-mediated cellular changes are frequently induced in cells exposed to cytotoxic drugs, UV, or g-irradiation (31, 32) , and ROS is a mediator of caspaseindependent cell death (33). We here examined whether evodiamine affects the cellular levels of peroxide by measuring the changes in the fluorescence using 2 ¶,7 ¶-dichlorodihydrofluorescein diacetate. As shown in Fig. 4A , treatment with evodiamine markedly increased the 2 ¶,7 ¶-dichlorodihydrofluorescein diacetate -derived fluorescence. This evodiamine-mediated increase in fluorescence was markedly inhibited by pretreatment with antioxidant NAC. Then, we next asked whether ROS generation induced by evodiamine is directly associated with the induction of apoptosis. However, as shown in Fig. 4B , pretreatment with NAC did not prevent evodiamine-induced increase of sub-G 1 population. In addition, pretreatment with NAC prevented neither the production of 60-kDa cleavage of PLC-g1 nor the degradation of procaspase-3 (Fig. 4C) . These data indicate that ROS generation is not critical for the induction of apoptosis by evodiamine.
Evodiamine-Induced Caspase-Independent Pathway Was Mediated by AIF Translocation
Because AIF is involved in induction of apoptotic cell death through caspase-independent pathway, we examined whether AIF plays a role in evodiamine-induced apoptotic cell death. Translocation of AIF was analyzed by the observation of its release from mitochondria and translocation to the nucleus by confocal microscopy. As shown in Fig. 5 , analysis by confocal microscopy showed that AIF was translocated into the nucleus and caused nuclear condensation after treatment with evodiamine. In addition, caspase inhibitor z-VAD-fmk did not affect AIF translocation into the nucleus after the evodiamine treatment. These results suggest that evodiamine-induced apoptotic cell death in U937 cells is mediated by the AIF translocation from mitochondria into nucleus via a caspase-independent pathway. It was reported that internucleosomal DNA fragmentation of nuclei induces chromatin condensation in apoptotic cells (34) . As shown in Fig. 5 , we found that the chromatin was less condensed in evodiamine plus z-VAD-fmk-treated cells compared with evodiamine-treated cells.
Evodiamine Could Induce Apoptosis Even in Bcl-2-Overexpressing Cells
Increased expression level of Bcl-2 in leukemia cells is correlated with elevated resistance to cytotoxic drugs (35) . Thus, bypassing this chemoresistance by Bcl-2 is an important therapeutic strategy. We first established Bcl-2-overexpressing cells. U937 cells were transfected with an expression vector containing Bcl-2 cDNA. After 4 weeks, geneticin-resistant (G418) cells were isolated and the relative expression level of Bcl-2 was determined by Western blot. In our previous study, we showed that U937/Bcl-2 cells exhibited approximately 3-to 4-fold increase in Bcl-2 expression compared with cells containing empty vector only (36) . We here evaluated whether evodiamine could induce cell death even in Bcl-2-overexpressing leukemia cells. As shown in Fig. 6A , overexpression of Bcl-2 did not completely prevent the production of cleavage products of PLC-g1 and PARP and the degradation of XIAP and procaspase-3. In addition, overexpression of Bcl-2 did not completely prevent evodiamine-induced cell death as determined by accumulation of sub-G 1 phase (Fig. 6B) , which suggests that evodiamine can bypass the inhibition of apoptosis originated from increased expression of Bcl-2 in leukemia cells.
Because evodiamine was revealed to induce apoptosis in U937 cells both by caspase-dependent and caspaseindependent pathways, we next examined whether induction of cell death by evodiamine in Bcl-2-overexpressing U937 cells is caspase dependent or caspase independent. z-VAD-fmk pretreatment completely prevented the production of cleavage products of PLC-g1 and the degradation of procaspase-3 and XIAP in Bcl-2-overexpressing U937 cells (Fig. 7A) . z-VAD-fmk pretreatment abolished DEVDase activity, which was maintained with a lower level in Bcl-2-overexpressing U937 cells compared with the U937/vector cells (Fig. 7B) . However, z-VAD-fmk pretreatment prevented only in part the accumulation of sub-G 1 phase in Bcl-2-overexpressing U937 cells as it did in U937/ vector cells (Fig. 7C) . Accordingly, we deliberately assumed that evodiamine at least in part could bypass the Bcl-2-mediated chemoresistance in leukemia cells via caspaseindependent apoptosis, which is supported by confocal microscopy data showing that Bcl-2 overexpression could not prevent the release from mitochondria and translocation onto nucleus of AIF (Fig. 7D) . 
Evodiamine Treatment Enhanced Cell Death in U937/ Akt and Renal Cancer Cells Overexpressing cFLIPs but Not in Human PBMCs
Previous studies have shown that constitutively activated Akt significantly protected cells from apoptosis (37) . To determine whether overexpression of Akt prevented evodiamine-induced apoptosis in leukemic cells, we used U937/ vector and U937/dominant-active Akt cells generated by transfection of the constitutively active Myc-tagged form of Akt. As shown in Fig. 8A and B, overexpression of constitutively active Akt did weakly inhibit evodiamineinduced apoptosis in leukemia cells. We examined next whether evodiamine could induce cell death in different type of cancer cells overexpressing antiapoptotic genes, such as cFLIPs. We established Caki/cFLIP cell lines transfected with the expression vectors encoding cFLIPs. Stable cFLIP-overexpressing cell lines were treated with various concentrations of evodiamine and examined cytotoxicity using FACS analysis. As shown in Fig. 8C , overexpression of cFLIPs was not enough to prevent evodiamine-induced apoptosis even if overexpression of cFLIPs prevented cisplatin-mediated apoptosis in human renal Caki cells. In addition, we examined whether evodiamine shows cytotoxicity in normal PBMCs. Primary PBMCs isolated from three volunteers were treated for 18 hours with 0.6 to 1 Amol/L evodiamine, and cell viabilities were assessed using cell counting kit-8 assay kit. As shown in Fig. 8D , we did not observe increased cell death in PBMCs treated with evodiamine compared with untreated PBMCs. These results suggest that treatment of evodiamine may have a therapeutic effect on leukemia cells overexpressing Bcl-2 and Akt and renal cancer cells overexpressing cFLIPs, which are resistant to many other chemotherapeutic drugs. 
Discussion
In the present study, evodiamine was found to exhibit significant antitumor activity against human leukemic cancer cells. Evodiamine-induced apoptosis was mediated by two different types of pathways (e.g., caspasedependent and caspase-independent pathways) in human U937 leukemia cells. We also found that evodiamine significantly induced apoptosis in both human leukemia and renal cancer cells that are overexpressed antiapoptotic proteins, including Bcl-2, Akt, and cFLIPs, whereas evodiamine did not cause significant normal PBMC death.
Multiple myeloma and acute myelogenous leukemia are cancers with high mortality rates, where novel strategies are required to improve on current treatment standards (38) . To overcome drug resistance and improve clinical outcomes, identification and evaluation of novel therapeutic agents that have less toxicity in normal cells for treatment of multiple myeloma and acute myelogenous leukemia are important and challenging tasks.
Evodiamine is an alkaloidal component isolated from Evodiae fructus and has anticarcinogenic, antiproliferative, and antimetastatic effects (26 -29, 39) . However, the molecular mechanism involved in evodiamine-induced apoptosis was poorly understood. In this study, we tested whether evodiamine treatment could be a new possibility for the treatment of human leukemia and examined the mechanism of evodiamine-induced apoptosis in human leukemia cells. We observed that evodiamine activated the mitochondrial caspase-dependent apoptotic pathway in dose-and time-dependent manners in U937 cells, which were partly prevented by pretreatment of a pancaspase inhibitor z-VAD-fmk. This result suggested that evodiamine-induced apoptosis was mediated by caspaseindependent as well as caspase-dependent apoptotic pathways. Previous reports have shown that caspasedependent pathways play essential roles in evodiamineinduced apoptosis (26) . They have shown that z-VAD-fmk and z-DEVD effectively prevented evodiamine-induced DNA fragmentation and apoptosis in HeLa cells. However, in another study, evodiamine-induced cell death in A375-S2 cells was partially prevented by z-VAD-fmk treatment (40) . Furthermore, evodiamine was shown to induce necrosis and caspase inhibitors failed to block A375-S2 cell death induced by evodiamine (27, 40) . Our data are consistent with these previous findings (27, 40) .
We firstly define the caspase-independent cell death machinery involved in the alternate pathway activated by evodiamine. To examine which type of cell death is induced by evodiamine, evodiamine-treated cells were stained with FITC-conjugated Annexin V and 7-AAD. As shown in Fig. 3 , caspase-independent cell death was not caused by necrotic cell death. Mitochondrial ROS are used as active mediators in the regulation of cell death, including caspase-dependent and caspase-independent pathways and necrosis (41 -43) . Evodiamine exposure leads to increase of ROS accumulation, but inhibition of ROS by NAC did not prevent evodiamine-induced apoptosis, indicating that ROS generation was not involved in evodiamine-mediated cell death.
It has been reported that AIF mediates cell death through a caspase-independent pathway. Mitochondrial AIF translocates to the nucleus on death stimuli and initiates nuclear condensation that leads to large-scale chromatin fragmentation followed by the cell death (44, 45) . Confocal microscopy showed that translocation of AIF into nucleus was found in U937 cells, which were not inhibited by z-VAD-fmk. This result suggested that the activation of caspase-independent apoptotic route was mediated through the translocation of AIF into nucleus.
Bcl-2 protein can act at multiple levels to inhibit apoptosis (46) , and increased expression level of Bcl-2 is correlated with elevated resistance to cytotoxic drugs in leukemia cells (35) . In this study, we showed that Bcl-2 overexpression partly attenuated caspase-dependent PLCg1 and PARP cleavage, decreased DEVDase activity, and degradation of XIAP proteins but did not completely prevent evodiamine-induced cell death, suggesting that Bcl-2 overexpression could partly block the caspasedependent pathway but not caspase-independent apoptotic pathway. In addition, we showed that translocation of AIF into nucleus was found in U937/Bcl-2 cells, which were not inhibited by z-VAD-fmk. This result suggested that evodiamine treatment can activate an AIF-mediated apoptotic cell death that is independent of caspase activation and not inhibited by overexpression of Bcl-2. Our data are consistent with the data from previous studies. Zhang et al. (47) reported that overexpression of Bcl-2 inhibited the early onset of caspase-dependent pathway but not the later caspase-independent pathway induced by addition of staurosporine through the AIF translocation to nucleus.
Tumor cells expressed several proteins that render them resistant to apoptosis. Increased activity of antiapoptotic proteins, such as Bcl-2, Akt, and cFLIPs, may result in aggressively growing and therapy-resistant tumors. In our present study, we showed that exogenous Bcl-2, constitutive active Akt, and cFLIP overexpression cannot prevent completely evodiamine-induced apoptosis in human leukemia cells and human renal Caki cells and that evodiamine did not cause significant normal PBMC death. These results raise the possibility that a strategy treating evodiamine may be effective against drug-resistant leukemia cells overexpressing Bcl-2 and Akt without any cytotoxicity to normal cells. These findings may have implications for the rational development of novel regimens in hematologic malignancies.
